Kalaris Launches Promising New Trial for Macular Degeneration
Kalaris has opened enrollment for a Phase 1b/2 multiple-ascending-dose study of TH103 in neovascular AMD, targeting up to 80...
Spyre Doses First Patient in Phase 2 Rheumatic Disease Trial
Spyre Therapeutics has dosed the first patient in SKYWAY, a randomized, placebo-controlled Phase 2 basket trial of SPY072, an...
What Happened In The Efzofitimod Sarcoidosis Phase 3 Study
Efzofitimod missed the primary endpoint in the Phase 3 EFZO-FIT study, reducing mean daily oral corticosteroid dose at week...
Valuable Insight: Breast Cancer ADC Market & Trials to 2030
More than 100 antibody-drug conjugates (ADCs) targeting breast cancer are in clinical development, with use expanding from late-line metastatic...
New Long-Term ALXN1840 Neurological Data for Wilson Disease
Statistically significant neurological improvement on the Unified Wilson Disease Rating Scale Parts II and III was sustained for up...
AI’s Transformative Role in Colorectal Cancer Screening
In the dynamic field of gastroenterology, AI is revolutionizing clinical practices, particularly in colorectal cancer screening. Dror Zur, CEO...
Redefining Imaging Workflows in Clinical Trials
At the Veeva R&D and Quality Summit in Boston, Moe Alsumidaie interviewed Jeff Sorenson, CEO of Yunu, and Steve...
What Research Sites Say They Need from Sponsors
At Veeva’s 2025 R&D & Quality Summit, site leaders described how brittle identity systems, sprawling vendor networks, and poorly...
Lexicon Submits Additional Zynquista® Data to FDA for Diabetes
Lexicon submitted additional clinical data to the FDA from three ongoing investigator-initiated studies of sotagliflozin to address the agency’s...
Pasithea NF1 Trial Advances to Cohort 2 on Positive Safety
No dose-limiting toxicities were observed in the first three patients treated with PAS-004 at the initial dose in Pasithea’s...